|
23.01.2025 22:31:40
|
Greenwich LifeSciences Adds Harvard And Johns Hopkins To FLAMINGO-01
(RTTNews) - Greenwich LifeSciences, Inc. (GLSI), a Texas-based biopharmaceutical company that conducts the Phase III FLAMINGO-01 trial of GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence, Thursday have announced the launch of new clinical sites in the US.
Harvard University and Johns Hopkins University have recently been added as participating sites for the FLAMINGO-01 trial in the US. Additionally, their principal investigators, Dr. Laura Spring and Dr. Cesar Santa-Maria, have joined the trial's Steering Committee.
The Steering Committee now includes leading experts in breast cancer oncology, representing prominent teaching hospitals in the US and four of the largest breast oncology networks across the US, Germany, France, and Spain.
GLSI is currently trading at $13 or 2.28% higher on the Nasdaq Capital Market.
Nachrichten zu Greenwich LifeSciences Inc Registered Shs
| Keine Nachrichten verfügbar. |
Analysen zu Greenwich LifeSciences Inc Registered Shs
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ LPL Finance
✅ Blackstone
✅ Ares Management
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Greenwich LifeSciences Inc Registered Shs | 13.08 | 2.99% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI geht fester aus dem Handel -- US-Handel endet mit Aufschlägen -- DAX schliesst nach neuem Rekord freundlich -- Börsen in Fernost letztlich mehrheitlich im PlusDer heimische Aktienmarkt zeigte sich am Donnerstag im Plus. Der deutsche Aktienmarkt notierte höher. Die US-Börsen schlossen höher. Asiens Börsen verbuchten am Donnerstag überwiegend Gewinne.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |